Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites
Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and developm...
Saved in:
Published in | Drug metabolism and disposition Vol. 38; no. 10; pp. 1900 - 1905 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
Elsevier Inc
01.10.2010
American Society for Pharmacology and Experimental Therapeutics |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites. |
---|---|
AbstractList | Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites. Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites.Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites. |
Author | Khetani, Salman R. Duignan, David B. Krzyzewski, Stacy Wang, Wendy WeiWei Obach, R. Scott |
Author_xml | – sequence: 1 givenname: Wendy WeiWei surname: Wang fullname: Wang, Wendy WeiWei – sequence: 2 givenname: Salman R. surname: Khetani fullname: Khetani, Salman R. – sequence: 3 givenname: Stacy surname: Krzyzewski fullname: Krzyzewski, Stacy – sequence: 4 givenname: David B. surname: Duignan fullname: Duignan, David B. – sequence: 5 givenname: R. Scott surname: Obach fullname: Obach, R. Scott email: r.scott.obach@pfizer.com |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23276863$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20595376$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUFv1DAQRi1URLeFK0fkC-KUxY7jxD5WS-kidcUBkLhFE3tSuUrsxXYq9sB_x9UuICH1NCPNe3P4vgty5oNHQl5ztua8bt7b2ZaFrZloVNc-Iysua14xpr-fkVUZrNJStufkIqV7xnjTCP2CnNdMaim6dkV-XaWEKc3oMw0jBbpzJoY95IzRo6VbLHswh4x0E8wy5SUi_XJIGWeaA71BjxHKcQf3IdLtMoOn1z9NxBzigYK3dONi8SA7f0c_xOWO7jDDECaXMb0kz0eYEr46zUvy7eP11822uv1882lzdVsZ0epcobJaWOgE6kZIy2uuOyM7qYHXjIvB1FZwo5TmSlgz6m4YxlGjYSNroFVKXJJ3x7_7GH4smHI_u2RwmsBjWFLfSclbUWtRyDcnchlmtP0-uhniof-TWAHengBIBqYxgjcu_eNE3bWqfXy0PnIlzpQijn8RzvrH6vpSXVlYf6yuCM1_gnG5xBZ8juCmpzV11LDk9-Aw9sk49Aati2hyb4N7Sv0NuDew6A |
CODEN | DMDSAI |
CitedBy_id | crossref_primary_10_1007_s00204_019_02585_5 crossref_primary_10_1039_C9LC00857H crossref_primary_10_3109_00498254_2014_956158 crossref_primary_10_1124_jpet_112_195834 crossref_primary_10_1039_C7IB00027H crossref_primary_10_1016_j_biotechadv_2013_03_007 crossref_primary_10_1016_j_tiv_2018_01_015 crossref_primary_10_1155_2017_9176937 crossref_primary_10_1124_dmd_124_001732 crossref_primary_10_1124_dmd_113_053397 crossref_primary_10_1126_scitranslmed_3005975 crossref_primary_10_3390_toxics10100566 crossref_primary_10_1093_toxsci_kfaa094 crossref_primary_10_1093_toxsci_kfv048 crossref_primary_10_1016_j_biotechadv_2014_01_003 crossref_primary_10_1124_dmd_114_057901 crossref_primary_10_3727_105221619X15638857793317 crossref_primary_10_1080_03602532_2016_1191843 crossref_primary_10_3389_fcell_2021_626805 crossref_primary_10_1002_hep_27621 crossref_primary_10_3389_fbioe_2021_730008 crossref_primary_10_1016_j_heliyon_2017_e00354 crossref_primary_10_1055_a_1981_5944 crossref_primary_10_3389_fmicb_2022_999366 crossref_primary_10_1124_dmd_118_081182 crossref_primary_10_1124_dmd_118_084293 crossref_primary_10_1146_annurev_virology_031413_085437 crossref_primary_10_1002_adhm_202202302 crossref_primary_10_1093_toxsci_kfx059 crossref_primary_10_1021_acs_chemrestox_8b00054 crossref_primary_10_1177_2211068214566939 crossref_primary_10_1039_C6LC01554A crossref_primary_10_2133_dmpk_DMPK_13_RG_105 crossref_primary_10_3109_00498254_2013_855836 crossref_primary_10_1016_j_cmet_2019_02_003 crossref_primary_10_1186_s12936_018_2198_4 crossref_primary_10_1080_17460441_2023_2238606 crossref_primary_10_3233_JCB_179012 crossref_primary_10_4155_bio_2016_0094 crossref_primary_10_1517_17460441_2012_651122 crossref_primary_10_1289_EHP12006 crossref_primary_10_1098_rstb_2017_0225 crossref_primary_10_1038_nprot_2015_128 crossref_primary_10_1016_j_bbrep_2017_04_004 crossref_primary_10_1517_17425255_2014_876006 crossref_primary_10_1016_j_tibtech_2016_08_001 crossref_primary_10_1093_toxsci_kfs326 crossref_primary_10_1002_jbm_a_36293 crossref_primary_10_1007_s11095_024_03787_y crossref_primary_10_1016_j_jcmgh_2017_11_012 crossref_primary_10_1021_acs_molpharmaceut_6b00396 crossref_primary_10_1124_dmd_115_066688 crossref_primary_10_1124_dmd_123_001638 crossref_primary_10_1038_scibx_2011_843 crossref_primary_10_1063_5_0051765 crossref_primary_10_1039_C2TX20051A crossref_primary_10_2174_1574888X17666220614160957 crossref_primary_10_1002_em_22077 crossref_primary_10_1093_toxsci_kfab018 crossref_primary_10_1124_dmd_113_055897 crossref_primary_10_3109_00498254_2011_621985 crossref_primary_10_1517_17460441_2015_1032241 crossref_primary_10_1016_j_dmpk_2025_101478 crossref_primary_10_1124_dmd_118_083295 crossref_primary_10_1124_dmd_112_046425 crossref_primary_10_3390_v15010158 crossref_primary_10_1016_j_jcmgh_2017_11_007 crossref_primary_10_1016_j_xphs_2018_03_001 crossref_primary_10_1002_biot_201800347 crossref_primary_10_1124_dmd_115_066431 crossref_primary_10_1089_nat_2013_0456 crossref_primary_10_1124_dmd_118_082867 crossref_primary_10_1080_03602532_2021_1922435 crossref_primary_10_1002_cptx_23 crossref_primary_10_1124_dmd_114_057026 crossref_primary_10_1016_j_biotechadv_2013_10_006 crossref_primary_10_1124_dmd_115_066027 crossref_primary_10_3109_00498254_2011_562330 crossref_primary_10_2174_1872312814666201202112610 crossref_primary_10_1002_cpt_2691 crossref_primary_10_1016_j_drudis_2011_02_012 crossref_primary_10_1016_j_chom_2013_06_005 crossref_primary_10_1021_acs_chemrestox_6b00150 crossref_primary_10_1177_1535370217708976 crossref_primary_10_1124_pharmrev_120_000238 crossref_primary_10_1080_03602532_2024_2370330 crossref_primary_10_1016_j_tiv_2014_05_007 crossref_primary_10_1517_17425255_2012_693161 crossref_primary_10_1124_dmd_115_067348 crossref_primary_10_1124_dmd_115_065326 crossref_primary_10_12688_openreseurope_13335_1 crossref_primary_10_1124_dmd_113_055947 crossref_primary_10_1517_17425255_2012_693159 crossref_primary_10_3389_fphar_2019_01093 crossref_primary_10_1021_acs_jmedchem_9b01840 crossref_primary_10_3389_ftox_2023_1051483 crossref_primary_10_1016_j_apsb_2022_03_009 crossref_primary_10_3109_10408444_2012_682115 crossref_primary_10_1002_jbt_21469 crossref_primary_10_1016_j_tiv_2018_01_023 crossref_primary_10_1177_1535370214531872 crossref_primary_10_1089_adt_2013_525 crossref_primary_10_1124_dmd_115_063495 crossref_primary_10_1016_j_copbio_2011_05_512 crossref_primary_10_1080_00498254_2017_1395927 crossref_primary_10_1002_jat_3091 crossref_primary_10_1124_dmd_120_000013 crossref_primary_10_1124_dmd_113_055715 crossref_primary_10_1124_dmd_113_053397fullarticlecorrection crossref_primary_10_1124_dmd_115_067173 crossref_primary_10_1002_jat_3805 crossref_primary_10_1124_dmd_115_067850 |
Cites_doi | 10.1021/tx8004357 10.1021/tx900124j 10.1021/tx800415j 10.4155/bio.09.98 10.1517/17425255.4.10.1279 10.1021/tx8004086 10.1080/03602530601093489 10.1016/S0090-9556(24)15179-3 10.1038/nbt1361 |
ContentType | Journal Article |
Copyright | 2010 American Society for Pharmacology and Experimental Therapeutics 2015 INIST-CNRS |
Copyright_xml | – notice: 2010 American Society for Pharmacology and Experimental Therapeutics – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1124/dmd.110.034876 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-009X |
EndPage | 1905 |
ExternalDocumentID | 20595376 23276863 10_1124_dmd_110_034876 S0090955624025157 |
Genre | Journal Article |
GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YCJ YHG ZGI ZXP ~KM AALRI AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c369t-e8d93da73e9435d12197c5759a12013bc2d31c889183dcf97bbff9ec0f04a6883 |
ISSN | 0090-9556 1521-009X |
IngestDate | Thu Jul 10 18:09:28 EDT 2025 Mon Jul 21 05:43:51 EDT 2025 Mon Jul 21 09:16:56 EDT 2025 Tue Jul 01 05:28:21 EDT 2025 Thu Apr 24 23:03:56 EDT 2025 Sun Apr 06 06:53:03 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | CP-122721 HCM CP-533536 ADME CP-547632 CP-690550 CJ-13610 HPLC Human Drug Evaluation Mixed cell culture Hepatocyte Digestive system Metabolite Liver In vitro |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c369t-e8d93da73e9435d12197c5759a12013bc2d31c889183dcf97bbff9ec0f04a6883 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 20595376 |
PQID | 755163293 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_755163293 pubmed_primary_20595376 pascalfrancis_primary_23276863 crossref_primary_10_1124_dmd_110_034876 crossref_citationtrail_10_1124_dmd_110_034876 elsevier_sciencedirect_doi_10_1124_dmd_110_034876 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-10-01 |
PublicationDateYYYYMMDD | 2010-10-01 |
PublicationDate_xml | – month: 10 year: 2010 text: 2010-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Bethesda, MD |
PublicationPlace_xml | – name: Bethesda, MD – name: United States |
PublicationTitle | Drug metabolism and disposition |
PublicationTitleAlternate | Drug Metab Dispos |
PublicationYear | 2010 |
Publisher | Elsevier Inc American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: Elsevier Inc – name: American Society for Pharmacology and Experimental Therapeutics |
References | Smith, Obach (bib10) 2009; 22 Atrakchi (bib2) 2009; 22 Hewitt, Lechón, Houston, Hallifax, Brown, Maurel, Kenna, Gustavsson, Lohmann, Skonberg (bib5) 2007; 39 Prakash, Kamel, Gummerus, Wilner (bib7) 1997; 25 Robison, Jacobs (bib8) 2009; 1 Anderson, Luffer-Atlas, Knadler (bib1) 2009; 22 Wynalda, Hauer, Wienkers (bib11) 2000; 28 Slatter, Stalker, Feenstra, Welshman, Bruss, Sams, Johnson, Sanders, Hauer, Fagerness (bib9) 2001; 29 Khetani, Bhatia (bib6) 2008; 26 Guillouzo, Guguen-Guillouzo (bib4) 2008; 4 Dalvie, Obach, Kang, Prakash, Loi, Hurst, Nedderman, Goulet, Smith, Bu (bib3) 2009; 22 Khetani (10.1124/dmd.110.034876_bib6) 2008; 26 Robison (10.1124/dmd.110.034876_bib8) 2009; 1 Slatter (10.1124/dmd.110.034876_bib9) 2001; 29 Smith (10.1124/dmd.110.034876_bib10) 2009; 22 Prakash (10.1124/dmd.110.034876_bib7) 1997; 25 Guillouzo (10.1124/dmd.110.034876_bib4) 2008; 4 Wynalda (10.1124/dmd.110.034876_bib11) 2000; 28 Atrakchi (10.1124/dmd.110.034876_bib2) 2009; 22 Hewitt (10.1124/dmd.110.034876_bib5) 2007; 39 Dalvie (10.1124/dmd.110.034876_bib3) 2009; 22 Anderson (10.1124/dmd.110.034876_bib1) 2009; 22 |
References_xml | – volume: 1 start-page: 1193 year: 2009 end-page: 1200 ident: bib8 article-title: Metabolites in safety testing publication-title: Bioanalysis – volume: 22 start-page: 267 year: 2009 end-page: 279 ident: bib10 article-title: Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment publication-title: Chem Res Toxicol – volume: 26 start-page: 120 year: 2008 end-page: 126 ident: bib6 article-title: Microscale culture of human liver cells for drug development publication-title: Nat Biotechnol – volume: 25 start-page: 863 year: 1997 end-page: 872 ident: bib7 article-title: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans publication-title: Drug Metab Dispos – volume: 28 start-page: 1014 year: 2000 end-page: 1017 ident: bib11 article-title: Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes publication-title: Drug Metab Dispos – volume: 22 start-page: 243 year: 2009 end-page: 256 ident: bib1 article-title: Predicting circulating human metabolites: how good are we? publication-title: Chem Res Toxicol – volume: 4 start-page: 1279 year: 2008 end-page: 1294 ident: bib4 article-title: Evolving concepts in liver tissue modeling and implications for in vitro toxicology publication-title: Expert Opin. Drug Metab Toxicol – volume: 22 start-page: 357 year: 2009 end-page: 368 ident: bib3 article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites publication-title: Chem Res Toxicol – volume: 29 start-page: 1136 year: 2001 end-page: 1145 ident: bib9 article-title: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [ publication-title: Drug Metab Dispos – volume: 39 start-page: 159 year: 2007 end-page: 234 ident: bib5 article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies publication-title: Drug Metab Rev – volume: 22 start-page: 1217 year: 2009 end-page: 1220 ident: bib2 article-title: Interpretation and considerations on the safety evaluation of human drug metabolites publication-title: Chem Res Toxicol – volume: 25 start-page: 863 year: 1997 ident: 10.1124/dmd.110.034876_bib7 article-title: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans publication-title: Drug Metab Dispos – volume: 22 start-page: 357 year: 2009 ident: 10.1124/dmd.110.034876_bib3 article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites publication-title: Chem Res Toxicol doi: 10.1021/tx8004357 – volume: 22 start-page: 1217 year: 2009 ident: 10.1124/dmd.110.034876_bib2 article-title: Interpretation and considerations on the safety evaluation of human drug metabolites publication-title: Chem Res Toxicol doi: 10.1021/tx900124j – volume: 22 start-page: 267 year: 2009 ident: 10.1124/dmd.110.034876_bib10 article-title: Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment publication-title: Chem Res Toxicol doi: 10.1021/tx800415j – volume: 1 start-page: 1193 year: 2009 ident: 10.1124/dmd.110.034876_bib8 article-title: Metabolites in safety testing publication-title: Bioanalysis doi: 10.4155/bio.09.98 – volume: 29 start-page: 1136 year: 2001 ident: 10.1124/dmd.110.034876_bib9 article-title: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects publication-title: Drug Metab Dispos – volume: 4 start-page: 1279 year: 2008 ident: 10.1124/dmd.110.034876_bib4 article-title: Evolving concepts in liver tissue modeling and implications for in vitro toxicology publication-title: Expert Opin. Drug Metab Toxicol doi: 10.1517/17425255.4.10.1279 – volume: 22 start-page: 243 year: 2009 ident: 10.1124/dmd.110.034876_bib1 article-title: Predicting circulating human metabolites: how good are we? publication-title: Chem Res Toxicol doi: 10.1021/tx8004086 – volume: 39 start-page: 159 year: 2007 ident: 10.1124/dmd.110.034876_bib5 article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies publication-title: Drug Metab Rev doi: 10.1080/03602530601093489 – volume: 28 start-page: 1014 year: 2000 ident: 10.1124/dmd.110.034876_bib11 article-title: Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes publication-title: Drug Metab Dispos doi: 10.1016/S0090-9556(24)15179-3 – volume: 26 start-page: 120 year: 2008 ident: 10.1124/dmd.110.034876_bib6 article-title: Microscale culture of human liver cells for drug development publication-title: Nat Biotechnol doi: 10.1038/nbt1361 |
SSID | ssj0014439 |
Score | 2.3565054 |
Snippet | Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety.... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1900 |
SubjectTerms | Biological and medical sciences Cells, Cultured Chromatography, High Pressure Liquid Coculture Techniques - methods Cryopreservation Hepatocytes - metabolism Humans Medical sciences Metabolic Detoxication, Phase I Metabolic Detoxication, Phase II Models, Biological Molecular Structure Pharmaceutical Preparations - chemistry Pharmaceutical Preparations - metabolism Pharmacology. Drug treatments Predictive Value of Tests Tandem Mass Spectrometry |
Title | Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites |
URI | https://dx.doi.org/10.1124/dmd.110.034876 https://www.ncbi.nlm.nih.gov/pubmed/20595376 https://www.proquest.com/docview/755163293 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLay7mXSNO3e7FL5YeoeUjqCCeDHqGVLFiXaJVG6viADpurUQpQQaZ20v7vfsWNsjDMl2kWKkMGAA-fD5xyfG0KviJPFMOnBh8QC13I9xiyaEN_KOO85IF7QoLKYjifeYOa-P-udtVo_Da-ldRkfJ9-3xpX8D1XhGNBVRMn-A2X1TeEAtIG-sAUKw_avaNzXaTVlmONYeNctqoyZMHsCS4F2kdyUojSdTLHBVYpyIXLKjNOlKD70tViq5fzwG4iRleFdrKifXC6Tqr5XftE5Xa4vOmNeAmpE3PLKFGurvmvVp6pupJfaI0zP_OEQfp15XwZKzXme6hX90SCc9idDuUp9VVkWdNen8y_n4fzzSPaWLNFXnc6G7yb9ifbOV0Wk1TKGcAmxN1xCavuU6az6ocneLZ86NKseTJsANXNd06a2RXsyW3k9xZPAhLJtTNggD9kG84fd3nbG4riAhvQ6FXETxzYBPW9LBu_fOKv2dwSxFdQ6j9xCtx1QZ0SljdHHxtrlukSqaeqvq-SiMOabzRF3CU93F2wFn3Qma7HsVpYqoWl6H91T2g7uS-g-QC2eP0SH6oXfHGHz5R7hQ2yS4hH60eAbFxlmeBPfuME31vjGEt-4LHCNb1zhG1f4xhrfGCiNDXxjgWFs4Psxmr0NpycDS5ULsRLi0dLiQUpJynzCKegAaRd4sZ-I-rOsC4AjceKkpJsEAQUuliYZ9eM4yyhP7Mx2mRcE5Anay4uc7yMc-CmNY-KD7pG6jGUxEYk04VyaZl5GSBtZNR2iROXSFyVdrqJKp3bcCOgGDTuSdGuj1_r8hcwis_PMbk3WSMnAUraNAIk7rznYoL8eooZdG-EaEBFwD2ESZDkv1qvIF3ZyAiJ_Gz2VQGkuhocXuZ6e_enuz9Gd5oN-gfbK5Zq_BEm9jA8qmP8Ccj_u0g |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+a+Micropatterned+Hepatocyte+Coculture+System+to+Generate+Major+Human+Excretory+and+Circulating+Drug+Metabolites&rft.jtitle=Drug+metabolism+and+disposition&rft.au=WEIWEI+WANG%2C+Wendy&rft.au=KHETANI%2C+Salman+R&rft.au=KRZYZEWSKI%2C+Stacy&rft.au=DUIGNAN%2C+David+B&rft.date=2010-10-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.volume=38&rft.issue=10&rft.spage=1900&rft.epage=1905&rft_id=info:doi/10.1124%2Fdmd.110.034876&rft.externalDBID=n%2Fa&rft.externalDocID=23276863 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |